Cite
SAT0643 FACIT-FATIGUE TO PROMIS-FATIGUE CROSS-WALKED DATA FROM MONARCH, MOBILITY AND TARGET RANDOMIZED CLINICAL TRIALS OF SARILUMAB FOR THE TREATMENT OF MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA)
MLA
Toshio Kimura, et al. “Sat0643 Facit-Fatigue to Promis-Fatigue Cross-Walked Data from Monarch, Mobility and Target Randomized Clinical Trials of Sarilumab for the Treatment of Moderately-To-Severely Active Rheumatoid Arthritis (Ra).” Saturday, 15 June 2019, May 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........1d67bf91647471d826f9b150c6c1d0ec&authtype=sso&custid=ns315887.
APA
Toshio Kimura, David Cella, Susan Boklage, & Clifton O. Bingham. (2019). Sat0643 Facit-Fatigue to Promis-Fatigue Cross-Walked Data from Monarch, Mobility and Target Randomized Clinical Trials of Sarilumab for the Treatment of Moderately-To-Severely Active Rheumatoid Arthritis (Ra). Saturday, 15 June 2019.
Chicago
Toshio Kimura, David Cella, Susan Boklage, and Clifton O. Bingham. 2019. “Sat0643 Facit-Fatigue to Promis-Fatigue Cross-Walked Data from Monarch, Mobility and Target Randomized Clinical Trials of Sarilumab for the Treatment of Moderately-To-Severely Active Rheumatoid Arthritis (Ra).” Saturday, 15 June 2019, May. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........1d67bf91647471d826f9b150c6c1d0ec&authtype=sso&custid=ns315887.